https://doi.org/10.31288/oftalmolzh201346166

Effect of transport taurine antagonist — ? -alanine on biochemical indicators in the retina animals experimental diabetes

K. P. Pavlyuchenko, E. V. Sorokina 

Донецкий национальный медицинский университет им. М. Горького

Key words: experimental diabetes, retina, mitochondria, lysosomes, taurine.

Studied indicators of functional intracellular structures of the retina (the mitochondria and lysosomes) in animals with experimental streptozotocin diabetes in violation of taurine transport by antagonist — ? -alanina. Research conducted on two groups of animals-1 (main) received stern antagonist of taurine 1 % ? -alanine and 2 — (control) with the usual diet pitaniyalzuchali active free form of the lysosomal enzyme acid phosphatase and mitochondrial enzyme systems (activity of succinate dehydrogenase, malate dehydrogenase, pyruvate dehydrogenase, a-ketodegidrogenazy, NADH oxidase, cytochrome oxidase, ATPase, glutamate) in 2 and 6 months. Activity of the mitochondrial matrix enzyme systems of internal and external membrane transport of taurine in violation of his antagonist ? -alanine reduced by 16 % and 22 % compared with that of the animals with diabetes who did not receive ? -alanine . Primenenie causes a severe disturbance of the stability of the lysosomal membrane of the retina at 6 month term streptozotocin diabetes, the degree of labilization of lysosomes increased by 16,8 %.

References

1.Balabolkin MI, Kreminskaya MI. Diabetic neuropathy. Zhurn. nevrolgii i psikhiatrii im. S. S. Korsakova. 2000; 10(10): 57- 64. Russian.

2.Veselovskaya ZV. Vision complications of diabetes. Prak-tychna angiologiia. 2006; 3: 56-8. Russian.

3.Yevgrafov VYu. Diabetic retinopathy: pathogenesis, diag-nosis, treatment: author's abstract. MD. M.; 1996. 47 p.

4.Leus NF. Metabolic mechanisms of development and prospects of medical treatment of diabetic retinopathy. Oftalmol Zh. 2003; 5: 75- 80. Russian.

5.Maltsev EV, Rodin SS, Chernyayeva SN. Diabetic retinip-athy, mechanism of development. Oftalmol Zh. 2003; 2: 82-8. Russian.

6.New methods of biochemical analysis. Publ. of Leningrad University; 1991. 395 p.

7.Oleinik TV. Oxidative damage to the retinal pigment epi-thelium in the simulation of streptozotocin-induced diabetes. Oftalmol Zh. 2005; 3: 47-9. Russian.

8.Pavlyuchenko KP, Oleinik TV. State of the lysosomal mem-brane and the retinal pigment epithelium and peroxidation processes in the introduction of the complex of functionally related coenzymes to animals with streptozotocin diabetes. Current issues of medical science and practice: Collection of science papers. 2006. 2(70): 209- 16.

9.Rebrova OYu. Statistic analysis of medical data. Using soft-ware package STATISTICA. M.: Media Sfera; 2002. 312 p.

10.Arany E, Strutt B, Romanus P. Taurine supplements in early life alterated islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic rats. Diabetologia. 2004; 47: 1831-7.
Crossref

11.Askwith T, Zeng W, Eggo M. C. Oxidative stress and dys-regulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy. Am. J. Physiol. Endocrinol. Metab. 2009;. 297: E620-E628.
Crossref

12.Birdsall TC. Therapeutic applications of taurine. Altern. Med. Rev. 1998; 3(2): 128-36.

13.Bergmeyer HU. Methoden der enzymatischen Analyse. He-rausgegeben von H. U. Bergmeyer. Berlin; 1986. 2056- 9.

14.Bloomgarden ZT. Diabetic retinopathy and diabetic neu-ropathy. Diabetes Care. 2007; 30(3): 760-5.
Crossref

15.Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813-20.
Crossref

16.Cai X-L, W&ng F, Ji L. Risk factors of diabetic retinopathy in type 2 diabetic patients. Chin. Med. J. 2006; 119(10): 822-6.
Crossref

17.Caldwell RB, Bartoli M, Behzadian MA. Vascular endothe-lial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug. Targets. 2005; 6(4): 511-24.
Crossref

18.Chang KJ. Effect of taurine and beta-alanine on morpho-logical changes of pancreas in streptozotocin-induced rats.Adv. Exp. Med. Biol. 2000; 483: 571-7.
Crossref

19.Dervan E, Lillis D, Flynn L. Factors that influence the patient uptake of diabetic retinoparthy screening. Irish. J. Med. Sci. 2008; 177: 303-8.
Crossref

20.Di Leo MAS, Santini SA, Cercone S. Chronic taurine supplementation ameliorates oxidative stress and Na+K+ATPase impairment in the retina of diabetic rats.Amino Acids. 2002; 23: 401-6.

21.Di Leo MAS, Ghirlanda G, Silvery NG. Potential therapeutic effect of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations. Free Rad. Res. 2003;37(3): 323-30.
Crossref

22.Fong DS, Aiello LP, Ferris FL, Klein RK. Diabetic retinopathy. — 2004; 27: 2540-53.

23.Franconi F, Loizzo A, Ghirlanda G. Taurine supplementation and diabetes mellitus. Curr. Opin. Clin. Nutr. Metab.Care. 2006; 9(1): 32-6.

24.Franconi F, Leo Di, Bennardini F. Is taurine benefical in reducing risk factors for diabetes mellitus. Neurochem. Res.2004; 29(1): 143-50.

25.Lang GE. Pharmacological treatment of diabetic retinopathy. Ophthalmologica. 2007; 221(2): 112-7.

26.Pan H-Z, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabeticretinopathy. Br. J Ophthalmol. 2008; 92: 548-51.

27.Speicher MA, Danis RP, Criswell M. Pharmacologic therapy for diabetic retinopathy. Expert Opion Emerg Drugs.2003; 8 (1): 239-50.

28.Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. Scientific World J. 2008; 8: 98- 120.
Crossref